Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition.

Tie C, Gao K, Zhang N, Zhang S, Shen J, Xie X, Wang JA.

PLoS One. 2015 Nov 10;10(11):e0142430. doi: 10.1371/journal.pone.0142430.

2.

Deficiency of Endogenous Acute-Phase Serum Amyloid A Protects apoE-/- Mice From Angiotensin II-Induced Abdominal Aortic Aneurysm Formation.

Webb NR, De Beer MC, Wroblewski JM, Ji A, Bailey W, Shridas P, Charnigo RJ, Noffsinger VP, Witta J, Howatt DA, Balakrishnan A, Rateri DL, Daugherty A, De Beer FC.

Arterioscler Thromb Vasc Biol. 2015 May;35(5):1156-65. doi: 10.1161/ATVBAHA.114.304776.

3.

Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE(-/-) mice and angiogenesis.

Escudero P, Navarro A, Ferrando C, Furio E, Gonzalez-Navarro H, Juez M, Sanz MJ, Piqueras L.

Br J Pharmacol. 2015 Jun;172(12):2946-60. doi: 10.1111/bph.13098.

4.

Experimental peripheral arterial disease: new insights into muscle glucose uptake, macrophage, and T-cell polarization during early and late stages.

Pellegrin M, Bouzourène K, Poitry-Yamate C, Mlynarik V, Feihl F, Aubert JF, Gruetter R, Mazzolai L.

Physiol Rep. 2014 Feb 25;2(2):e00234. doi: 10.1002/phy2.234.

5.

Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis.

Krauth D, Anglemyer A, Philipps R, Bero L.

PLoS Biol. 2014 Jan;12(1):e1001770. doi: 10.1371/journal.pbio.1001770.

6.

Combination therapy with atorvastatin and amlodipine suppresses angiotensin II-induced aortic aneurysm formation.

Takahashi K, Matsumoto Y, Do e Z, Kanazawa M, Satoh K, Shimizu T, Sato A, Fukumoto Y, Shimokawa H.

PLoS One. 2013 Aug 13;8(8):e72558. doi: 10.1371/journal.pone.0072558.

7.

CYP2J2 overexpression increases EETs and protects against angiotensin II-induced abdominal aortic aneurysm in mice.

Cai Z, Zhao G, Yan J, Liu W, Feng W, Ma B, Yang L, Wang JA, Tu L, Wang DW.

J Lipid Res. 2013 May;54(5):1448-56. doi: 10.1194/jlr.M036533.

8.

Efficacy and mechanism of angiotensin II receptor blocker treatment in experimental abdominal aortic aneurysms.

Iida Y, Xu B, Schultz GM, Chow V, White JJ, Sulaimon S, Hezi-Yamit A, Peterson SR, Dalman RL.

PLoS One. 2012;7(12):e49642. doi: 10.1371/journal.pone.0049642.

9.

Novel mechanisms of abdominal aortic aneurysms.

Lu H, Rateri DL, Bruemmer D, Cassis LA, Daugherty A.

Curr Atheroscler Rep. 2012 Oct;14(5):402-12. doi: 10.1007/s11883-012-0271-y. Review.

10.

PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways.

Camps J, García-Heredia A, Rull A, Alonso-Villaverde C, Aragonès G, Beltrán-Debón R, Rodríguez-Gallego E, Joven J.

PPAR Res. 2012;2012:616371. doi: 10.1155/2012/616371.

11.

The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome.

Putnam K, Shoemaker R, Yiannikouris F, Cassis LA.

Am J Physiol Heart Circ Physiol. 2012 Mar 15;302(6):H1219-30. doi: 10.1152/ajpheart.00796.2011. Review.

12.

Complex pathologies of angiotensin II-induced abdominal aortic aneurysms.

Daugherty A, Cassis LA, Lu H.

J Zhejiang Univ Sci B. 2011 Aug;12(8):624-8. doi: 10.1631/jzus.B1101002. Review.

Items per page

Supplemental Content

Support Center